The approvals FDA of 2012: we are making progress?
Only 13 drugs on 37 (35%) were licensed to Big Pharma. Ciò è in linea with i data of last 8 years, when the share of Big Pharma he swung between the 25% and the 40%.
Based on the data historians, only 4 or 5 Of these 13 drugs they will become blockbusters. The rest arriverà in media a circa $500 million. This non è sufficiente to support the sales of the top 13 pharmaceutical companies than in 2011 they were just under $ 400 billions of dollars. Despite the best intentions their managing directors ", ci si può aspettare a significant one turbulence more after you.
The companies that they need new drugs not there ottiene più. Since 2005, Abbott, AstraZeneca And Lilly they have altogether received 3 approvals NME (except those of image), a performance problematic for companies that, historically, have made a great contribution all’innovazione. Compared, the first 3 companies, Johnson & Johnson, GSK extension, Novartis they have received 31 approvals during the same period.
13 top pharmaceutical companies they spend approx $72 billion l’anno in R&D.